Phaseline

Companies › SN BioScience

SN BioScience: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SNB-101
Nanoparticle formulation of SN-38 (topoisomerase I inhibitor)
TOPO1Phase 1Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)Dec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07391813SNB-101Phase 1Patient is Not Suitable for Complete Surgical Resection With a Cytologically or Histologically Confirmed Small Cell Lung Cancer(SCLC)OncologyDec 2028

Targets

TOPO1 (1)

Companies with the same targets

Genmab

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.